Department of Experimental and Clinical Medicine and DENOTHE Center, University of Florence, Florence, Italy.
Immunology and Cell Therapy Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Eur J Immunol. 2019 Sep;49(9):1334-1343. doi: 10.1002/eji.201948156. Epub 2019 Aug 12.
During the last decades, progression of research has led to great achievements for treatment and therapy of several disabling disorders, particularly in the field of chronic inflammatory diseases. The increased knowledge of the molecular mechanisms operating in such diseases has represented the first step in this process, and the discovery of molecules able to interfere with the natural history of the diseases, has been the second. This review is focused on the effects of biologics on type 2 diseases such as asthma, chronic urticaria and atopic dermatitis, both biologics just approved for clinical application and also those that are currently undergoing clinical trials. We will also discuss aspects and emphasize clinical trials and recently published studies, as well as research that is currently in the progress, which will be highly relevant for basic immunologists. Likewise, we will cover aspects that are pertinent for clinical immunologists and highlight translational studies that are evaluating novel biologicals in animal models.
在过去的几十年中，研究的进展为治疗和治疗几种致残性疾病带来了巨大的成就，特别是在慢性炎症性疾病领域。对这些疾病中起作用的分子机制的深入了解是这一过程的第一步，而发现能够干扰疾病自然史的分子则是第二步。这篇综述集中讨论了生物制剂对 2 型疾病（如哮喘、慢性荨麻疹和特应性皮炎）的影响，包括刚刚批准临床应用的生物制剂和正在进行临床试验的生物制剂。我们还将讨论一些方面，并强调临床试验和最近发表的研究，以及目前正在进行的研究，这些研究对基础免疫学家非常重要。同样，我们将涵盖与临床免疫学家相关的方面，并强调正在动物模型中评估新型生物制剂的转化研究。
